Frontiers in Endocrinology · 10 authors, 9 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This randomized trial compared a telehealth model to in-person care in 55 adults with type 1 diabetes in a rural area. The telehealth model resulted in similar HbA1c control at 6 months but showed significant improvements in time in range, time above range, and quality of life.
This open-label randomized controlled trial compared a telehealth model to in-person care in 55 adults with type 1 diabetes on multiple daily injections in a rural area. The telehealth group demonstrated significant improvements in time in range and time above range, as well as a better score on the Diabetes Quality of Life questionnaire. Participant costs were lower in the telehealth group. The study was limited by its short follow-up period, higher time commitment for endocrinologists in the telehealth group, and the use of a non-standardized satisfaction questionnaire. The findings suggest the telehealth model is a safe, accepted, and comparable alternative to in-person care for this population, with potential benefits for glucose metrics and quality of life.
